Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.69 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.65 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL14853938 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056533 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL329746 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL10815678 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056827 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL375985 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Arauridine SCHEMBL359587 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL7752140 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL20987631 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL1804774 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117615774-A | PD-L1 binding peptides and peptide complexes and methods of use thereof | 弗莱德哈钦森癌症中心 | 2024-02-27 | — | — | CN | disclosed |
| US-20230183701-A1 | Modified Double-Stranded RNA Agents | BANK OF AMERICA, N.A. | 2023-06-15 | — | — | US | disclosed |
| US-20230110876-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2023-04-13 | — | — | US | disclosed |
| US-11549109-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220389424-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2022-12-08 | — | — | US | disclosed |
| US-11401517-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-114181942-A | Modified double-stranded RNA reagents | 阿尔尼拉姆医药品有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20220056448-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2022-02-24 | — | — | US | disclosed |
| US-20220002727-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-01-06 | — | — | US | disclosed |
| EP-3812462-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10612027-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10612024-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190241893-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2019-08-08 | — | — | US | disclosed |
| US-20190241891-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2019-08-08 | — | — | US | disclosed |
| US-10233448-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170275626-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2017-09-28 | — | — | US | disclosed |
| CN-107075516-A | Modified double-stranded RNA reagents | 阿尔尼拉姆医药品有限公司 | 2017-08-18 | — | — | CN | disclosed |
| WO-1996028190-A1 | NON-INVASIVE IMAGING OF GENE TRANSFER | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-09-19 | — | — | WO | disclosed |
| EP-0085084-A1 | COMBINED PREPARATION WITH SYNERGISTIC EFFECT | ROBUGEN GMBH PHARMAZEUTISCHE FABRIK (DE) | 1983-08-10 | — | — | EP | disclosed |
| WO-1983000436-A1 | COMBINED PREPARATION WITH SYNERGIC EFFECT | GAURI, KAILASH, KUMAR | 1983-02-17 | — | — | WO | disclosed |